PrecisionRx Compounding has issued a nationwide recall of three lots of compounded testosterone cypionate injections after sterility testing revealed bacterial contamination. The affected lots were distributed to clinics and pharmacies in 18 states between January and March 2026.
The FDA has received reports of four patients developing injection site infections potentially linked to the contaminated products. Healthcare providers are being notified to identify patients who received injections from the recalled lots and monitor for signs of infection.
The recall highlights ongoing concerns about quality control in the compounding pharmacy industry. FDA officials have called for stronger oversight and more frequent inspections of compounding facilities that produce sterile injectable medications.
